Wolverine blend (BPC-157 + TB-500)
"Wolverine" is a seller's name for BPC-157 and TB-500 mixed in one vial. Each ingredient can now be compounded on its own under the 2026 federal policy. The mixed vial cannot, and nobody has tested the combination in people.
- Legal lane: outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved.
- Evidence grade: D for the combination
- What is in it: BPC-157 and TB-500, commonly 10 mg of each
- Established human dose: none
What it is
A premixed vial of two repair peptides, BPC-157 and TB-500, also sold as "BPC/TB". It is marketed for injury recovery, tendons and ligaments. The name is taken from the Marvel character. It is a marketing term and does not describe a tested product.
What the evidence shows
There is no trial of this blend. Not a small one, and not a negative one.
The evidence that exists applies to each ingredient studied separately, and for both it is almost entirely animal work with no completed controlled human trials. The case for mixing them is that each is said to handle a different stage of repair. That is a hypothesis. Nobody has measured whether the pair works better than either alone.
The concern reached the FDA's advisory committee in July 2026. One member who voted against adding TB-500 to the compounding list cited the lack of basic data and the fact that it is being used in combination with other drugs.
Legal status
In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it.
- A vial of BPC-157 alone, from a licensed pharmacy, on a patient-specific prescription: within the policy.
- A vial of BPC-157 and TB-500 together: outside it.
- A clinician prescribing both separately, to be injected separately: back within it.
The practical consequence is supply. A seller offering this blend is either working outside the policy or is not a licensed compounding pharmacy at all.
Reported dosing
No dose has been established for this blend.
No human trial has tested it, so there is no label, no study and no documented prescriber consensus to report. The mixing tables and week-by-week schedules published by sellers are their own arithmetic applied to a product nobody has studied. Where we can report dosing for the individual ingredients, it is on each compound's own page, with the source shown.
Safety
- You cannot tell what worked. If you improve, you have learned nothing about which ingredient to keep.
- You cannot tell what went wrong. A reaction means stopping everything, with no way to find the cause except starting over one at a time.
- The mixture itself is unstudied. Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations.
- Quality is a separate risk. A pharmacy following the policy closely will not make a blend, so the product comes from outside that system.
Common questions
Is the Wolverine blend legal?
Not as a mixed vial. The October 2026 policy allows pharmacies to compound BPC-157 and TB-500 one at a time on prescription. A vial holding both falls outside it.
Has the Wolverine blend been tested in people?
No. There is no human trial of the combination, and the two ingredients have no completed controlled human trials of their own.
What dose of the Wolverine blend is used?
No dose has been established. Seller schedules are not based on any study of the blend.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition
- McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products
- Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy
- Nutritional Outlook: legal analysis that a BPC-157 and TB-500 blend falls outside the policy
- Healio: advisory committee discussion, including the combination-use concern raised on TB-500
- Healthy Male: the Wolverine stack as a marketing term
All three repair blends are compared on blends and stacks. To keep a private record of what you take, use the dose and progress log.